ExpreS2ion provides update on ABNCoV2 Phase III clinical trial
Hørsholm, Denmark, February 15, 2023– ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") today provides an update on Bavarian Nordic’s Phase III clinical trial for the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine. Today Bavarian Nordic announced that the top-line results are now anticipated around mid-2023 due to longer than expected recruitment times.Bavarian Nordic announced today that the top-line data from its Phase III clinical trial of the ABNCoV2 capsid virus-like particle (cVLP) based COVID-19 booster vaccine will be